Summarized by Masters of Longevity from FDA - Drugs.
FDA approved pirtobrutinib for relapsed or refractory mantle cell lymphoma.
Key Takeaways
- FDA granted accelerated approval based on response rates.
- Approval was supported by overall response and duration data.
- Confirmatory trials are required to verify clinical benefit.
